As global tobacco use patterns evolve, smoking, vaping & harm-reduction science is gaining importance in public health and pulmonology. Traditional smoking cessation programs now coexist with research into electronic nicotine delivery systems (ENDS), heated tobacco products, and nicotine replacement therapies. While vaping is promoted by some as a harm-reduction tool, its long-term respiratory effects remain under investigation. Smoking, vaping & harm-reduction science highlights the need for balanced messaging, particularly for youth and high-risk populations. Epidemiologic studies and toxicologic analyses are essential in defining risk thresholds and shaping regulatory policies. Health education, tobacco taxation, and product labelling reforms play complementary roles in prevention efforts. A nuanced, evidence-based approach is vital to reducing global lung disease burden without inadvertently creating new dependencies.
Title : Screening questionnaires for obstructive sleep apnea: An updated systematic review
Behzad Rahmati, Isfahan University of Medical Sciences, Iran (Islamic Republic of)
Title : Improving covid 19 candidate vaccine response through probiotics and micronutrient supplementation: Evaluating the role of TLR5
Zohre Eftekhari, Biotechnology Research Center, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Iatrogenic pneumothorax following nephrectomy: Case report
Chaimae Tahiri, National University Hospital Center of Fann, Senegal
Title : Towards the experience and view of personalized and precision pulmonology: An option for clinicians, geneticists and caregivers to realize the potential of genomics informed lung cancer care to secure the individualized human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Opioid induced hypoventilation and sleep related hypoxemia in a patient on buprenorphine naloxone an underrecognized problem.
Anusha Devarajan, University of Vermont Medical Center, United States